drugset / Trial / NCT05467748
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Phase 1/2
Recruiting
66 enrolled
VA Office of Research and Development
VA Greater Los Angeles Healthcare System · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2027-12-08
- Completion
- 2029-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tulmimetostat | Small molecule | 200 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 300 mg | Oral |